New onset of psoriasis during nivolumab treatment for lung cancer

J Dermatol. 2018 Mar;45(3):e55-e56. doi: 10.1111/1346-8138.14167. Epub 2017 Dec 4.

Authors

Satomi Chujo¹, Akihiko Asahina¹, Yuta Itoh¹, Kae Kobayashi², Hirohiko Sueki², Takaoki Ishiji¹, Yoshinori Umezawa¹, Hidemi Nakagawa¹

Affiliations

¹ Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
² Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.

PMID: 29205470
DOI: 10.1111/1346-8138.14167

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Humans
Lung Neoplasms / drug therapy*
Male
Nivolumab / adverse effects*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Psoriasis / diagnosis
Psoriasis / immunology*
Psoriasis / pathology
Skin / drug effects
Skin / immunology
Skin / pathology

Substances

Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab